PURPOSE: In @entity43 permanent remission may be provided with optimal cytoreductive surgery and adjuvant chemotherapy. However survival is short in @entity1 with residual macroscopic disease after surgery or recurrent @entity43 . Applicable maintenance therapies with low @entity137 are required to prolong progression-free survival (PFS) for @entity1 with no curative treatment options. In this study, we investigated the effect of maintenance metronomic oral @entity786 and @entity2879 (CE) in @entity43 @entity1 with post operative residual or recurrent disease. METHODS: Forty five @entity1 that received metronomic oral CE ( @entity786 50 mg/daily and @entity2879 50 mg for 1-5 days, every 21 days) as maintenance therapy for @entity66 due to incomplete surgical resection or recurrent @entity43 were evaluated. The time between the beginning of oral CE and disease progression was also evaluated. RESULTS: The mean @entity1 age was 58 years, the vast majority had @entity420 (78%) and received a mean of 2 (range 1-4) lines of various intravenous regimens for postoperative residual or recurrent disease. Mean duration of oral CE was 11.3 months (range 2.9-29). Median PFS was 10.3 months (range 7.9-12.8). Only 5 @entity1 discontinued treatment due to intolerance and grade 3-4 @entity137 was recorded in 3 @entity1 (7%). CONCLUSION: Maintenance metronomic oral CE treatment was found effective, minimally toxic and sustainable in @entity1 with macroscopic residual or recurrent @entity43 . However, randomized and placebo-controlled well designed studies are required.

Prolonged progression-free survival with maintenance metronomic oral @entity786 and @entity2879 treatment in macroscopic XXXX or recurrent/advanced stage @entity43 .

@entity43 :: ('MESH:D010051', 'Disease') :: ['advanced-stage ovarian cancer', 'ovarian cancer'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity420 :: ('MESH:D000230', 'Disease') :: ['serous adenocarcinoma']
@entity66 :: (MESH:D004194,Disease) :: ['residual disease']
